• Publications
  • Influence
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
TLDR
Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer. Expand
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
TLDR
The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction. Expand
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
TLDR
Bvacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer, and this trial was stopped after the interim analysis met the criteria for early stopping. Expand
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
TLDR
Examination of the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Expand
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
TLDR
A synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma and, on the basis of immunologic assays, 91% of patients could be successfully immunized with this peptide. Expand
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
TLDR
The multidisciplinary approach adopted at institutions is described, and recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy are provided. Expand
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
TLDR
IL-2 was more clinically active at maximal doses, although this did not produce an overall survival benefit, and the immunological factors which constrain the curative potential of IL-2 to only a small percentage of patients need to be further elucidated. Expand
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
TLDR
Treatment with BRAF inhibition enhances melanoma antigen expression and facilitates T-cell cytotoxicity and a more favorable tumor microenvironment, providing support for potential synergy of BRAF-targeted therapy and immunotherapy. Expand
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
TLDR
Large numbers of gene-modified tumor-reactive T cells can be safely given to patients, but these cells do not persist in large numbers long term, and future studies need to employ strategies to extend T cell persistence. Expand
Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-61
TLDR
It is demonstrated that although IL-21 induces death of resting B cells, it promotes differentiation of B cells into postswitch and plasma cells, explaining howIL-21 can be proapoptotic for B cells in vitro yet critical for Ag-specific Ig production in vivo. Expand
...
1
2
3
4
5
...